Image | Contributed
Grace Johnston, chief commercial officer for Quantum-Si.
December 21, 2022
Quantum-Si launches 'Platinum' tech for benchtop protein sequencing
Image | Contributed
Quantum Si Inc.’s Platinum next-generation single-molecule protein sequencing platform.
By Michelle Tuccitto Sullo
Guilford-based medical technology company Quantum-Si Inc. on Tuesday made its “Platinum” technology commercially available.
The company said Platinum provides next-generation, single-molecule protein sequencing. The technology can be used for proteomic research to advance drug discovery and health diagnostics.
Platinum costs $70,000, and at a size of about 19.5 inches by 8.5 inches, it can fit on a benchtop. Quantum-Si is now taking orders for Platinum and will begin shipping them to customers in the first quarter of 2023.
In the past, proteomics technology has involved larger and more expensive machinery. According to Quantum-Si, its new technology will “greatly improve” access to high-resolution protein sequencing data. The company anticipates that Platinum will accelerate “breakthroughs across scientific disciplines, from drug discovery to biotech,” ultimately improving people’s health.
Jonathan Rothberg, who founded Quantum-Si in 2013, said the desktop system is simple to use.
Rothberg, a serial entrepreneur, has also been involved in next-generation genome sequencing.
“We learned from the success of next-generation DNA sequencing how to move beyond big machines, expensive facilities and the need for significant training, and we saw the benefits of placing the power of sequencing into the hands of individual researchers,” Rothberg said.
Rothberg’s Butterfly Network similarly made ultrasound more convenient, with its handheld ultrasound device.
Jeff Hawkins, who joined as CEO of Quantum-Si in October, said next-generation protein sequencing “represents the vanguard of new therapeutic discovery.”
“Platinum delivers on a decade’s long mission to dramatically improve access and scalability of single-molecule protein sequencing,” Hawkins said.
Meanwhile, the company appointed Grace Johnston to the position of chief commercial officer, a role which involves overseeing all global commercial activity, including sales, marketing and customer support. She joins the company from Fortis Life Sciences, where she served as CCO for over two years.
Contact Michelle Tuccitto Sullo at msullo@newhavenbiz.com.
Most Recent
Most Recent
0 Comments